Skip to content

In'Oss™ (MBCP® Putty) Ortho

Study of the Osteoconductive Potential of the Injectable Bone Substitute In'Oss™ (MBCP® Putty) in the Filling of Orthopaedic Bone Defects

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06326827
Enrollment
100
Registered
2024-03-22
Start date
2025-03-31
Completion date
2027-03-31
Last updated
2025-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Extremity Injury, Orthopedic Disorder, Trauma Injury

Keywords

Proximal humerus, Distal radius, Distal femur, Proximal tibia, Distal tibia, Fracture, MBCP Putty, Bone defect reconstruction

Brief summary

Study of the osteoconductive potential of the injectable bone substitute In'Oss™ (MBCP® Putty) in the filling of orthopaedic bone defects to collect Post-Market Clinical Follow-up (PMCF) data for the CE-marked In'Oss™ (MBCP® Putty) device in the orthopaedic trauma surgery

Detailed description

The In'Oss™ (MBCP® Putty) device is an Injectable Bone Substitute (IBS) whose purpose is a bone gap and void filler. It forms a putty-like synthetic bone graft which molds to the shape of the defect. It is composed of Hydroxyapatite (HA), Beta Tricalcium Phosphate (ß-TCP) and a hydrogel and is presented in sterile syringes. The Injectable Bone Substitute In'Oss™ is intended for use to reconstruct bony voids or bone gaps of the skeletal system (e.g. extremities, spine and pelvis). The performances of the Injectable Bone Substitute In'Oss™ (MBCP® Putty) are the filling of bone defects and the bony ingrowth from local osseous tissue onto the surface of the product (osteoconduction process). The purpose of this study is primarily to collect Post-Market Clinical Follow-up (PMCF) data on the performance and safety of the CE marked In'Oss™ device in the orthopaedic application. The data and conclusions obtained from this study by the Sponsor Advanced Medical Solutions Ltd. (AMS) together with the manufacturer Biomatlante will be used to provide clinical evidence for the clinical evaluation process.

Interventions

DEVICEIn'Oss™ (MBCP® Putty)

Use of In'Oss™ (MBCP® Putty) in surgical procedure to correct epiphyso-metaphyseal and/or metaphyso-diaphyseal bone defect in one of the following anatomical locations: Proximal humerus, Distal radius, Distal femur, Proximal tibia, Distal tibia.

Sponsors

Advanced Medical Solutions Ltd.
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

1. Patient is male or female, 18 - 85 years old; 2. Patient is willing and able to give written informed consent; 3. Patient is able to comply with a prior medical examination; 4. Patient is or has been scheduled for a surgical procedure to correct epiphyso-metaphyseal and/or metaphyso-diaphyseal bone defect in one of the following anatomical locations: * Proximal humerus ▪ Distal radius * Distal femur ▪ Proximal tibia ▪ Distal tibia 5. Patient is willing and able to comply with the study procedures during surgery and the post-surgical follow up period, up to 12 months.

Exclusion criteria

1. Patient has had an infection in the same extremity within last 24 months; 2. Patient has signs of necrosis at the surgical site; 3. Patient has cellulitis; 4. Patient has granuloma or non-curetted cyst; 5. Patient has an history of uncontrolled diabetes; 6. Patient is alcoholic and/or heavy smoker (\> 20 cigarettes per day); 7. Patient has a congenital or acquired immunodeficiency; 8. Patient has severe bone loss (≥ 40cm3); 9. Patient is on long-term steroidal therapy or treatment acting on the calcium or phosphorus metabolism; 10. Patient is or has been scheduled for surgery that would involve intra-articular implantation of the study device; 11. Patient who has or had an uncontained bone defect created as a result of trauma injury or surgically created; 12. Patient was exposed to any radiation (e.g. X-Rays, handling of radiolabelled materials) other than the normal background radiation within the 12 months before the screening visit; 13. Patient is pregnant; 14. Patient who is an employee at the study site; 15. Patient is known to be non-compliant with medical treatment or follow-up 16. Patient has any significant or unstable medical/psychiatric condition that, in the opinion of the Investigator, would interfere with their ability to participate in the study; 17. Patient is currently enrolled or planning to enrol in another clinical study or treatment with another investigational drug/device that may interfere with the assessments, visits or outcomes of this study.

Design outcomes

Primary

MeasureTime frameDescription
Successful bone defect reconstruction in the extremitiesAt 12 months post-surgeryEvaluation of performance of the In'Oss™ (MBCP® Putty) through the achievement of successful bone fusion through radiological evaluation (X-Ray) within 12 months by assessing interdigitation in 3 out of 4 planes (anterior/posterior/lateral/medial).

Secondary

MeasureTime frameDescription
Evaluation of functional mobility restoration in the upper limb with PRO measuresWithin 12 months post-surgeryFunctional mobility restoration in the upper limb after use of In'Oss™ (MBCP® Putty) in bone defect reconstruction by scoring patient's physical disability and symptoms through patient-reported outcome measure (Quick Disabilities of the Arm, Shoulder and Hand (QuickDASH)
Evaluation of functional mobility restoration in the lower limb with PRO measureWithin 12 months post-surgeryFunctional mobility restoration in the lower limb after use of In'Oss™ (MBCP® Putty) in bone defect reconstruction by scoring patient's physical disability and symptoms through patient-reported outcome measure: Lower Extremity Functional Scale (LEFS)
Evaluation of patient's pain intensity with VAS pain scaleWithin 12 months post-surgeryPatient's pain intensity at trauma/surgical site evaluated with Visual Analog Scale (VAS) pain scale after use of In'Oss™ (MBCP® Putty) in bone defect reconstruction in the extremities. 0 = no pain; 10 = worst pain imagineable.
Evaluation of safety of In'OssWithin 12 months post-surgeryIncidence of device related Adverse Events after use of In'Oss™ (MBCP® Putty) in bone defect reconstruction in the extremities.
Evaluation of device usabilityWithin 12 months post-surgeryClinician satisfaction with use of In'Oss™ (MBCP® Putty) as per Instructions for Use (IFU) in bone defect reconstruction in the extremities. 0 = very unsatisfied; 5 = very satisfied.

Contacts

Primary ContactSusan Clark
susan.clark@admedsol.com01606863500
Backup ContactLoïc Limon-Duparcmeur
loiclimonduparcmeur@biomatlante.com01606863500

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026